{"organizations": [], "uuid": "9993450fadf5914f856adc4b2e018ec8cd17b088", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-seattle-genetics-to-acquire-cascad/brief-seattle-genetics-to-acquire-cascadian-therapeutics-idUSASB0C36G", "country": "US", "domain_rank": 408, "title": "BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-31T13:34:00.000+02:00", "replies_count": 0, "uuid": "9993450fadf5914f856adc4b2e018ec8cd17b088"}, "author": "", "url": "https://www.reuters.com/article/brief-seattle-genetics-to-acquire-cascad/brief-seattle-genetics-to-acquire-cascadian-therapeutics-idUSASB0C36G", "ord_in_thread": 0, "title": "BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics", "locations": [], "entities": {"persons": [], "locations": [{"name": "seattle", "sentiment": "none"}], "organizations": [{"name": "brief-seattle genetics to acquire cascadian therapeutics reuters", "sentiment": "negative"}, {"name": "brief-seattle genetics to acquire cascadian therapeutics", "sentiment": "negative"}, {"name": "barclays & jpmorgan-chase bank", "sentiment": "none"}, {"name": "seattle genetics inc", "sentiment": "none"}, {"name": "seattle", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 34 AM / in 9 minutes BRIEF-Seattle Genetics To Acquire Cascadian Therapeutics Reuters Staff \nJan 31 (Reuters) - Seattle Genetics Inc: \n* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE \n* SEATTLE GENETICS TO ACQUIRE CASCADIAN THERAPEUTICS, ADDING LATE-STAGE BREAST CANCER PROGRAM TO ITS ONCOLOGY PIPELINE \n* DEAL FOR $10.00 PER SHARE IN CASH, OR APPROXIMATELY $614 MILLION. \n* TRANSACTION WAS UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES \n* SEES REVENUE OF $128 MILLION TO $130 MILLION FOR THREE MONTHS ENDED DEC. 31 \n* SEATTLE GENETICS- UNDER TERMS OF DEAL, CO WILL COMMENCE TENDER OFFER ON/ABT FEB 8 TO BUY ALL OF OUTSTANDING SHARES OF STOCK OF CASCADIAN THERAPEUTICS \n* SEATTLE GENETICS - ‍IN CONNECTION WITH TRANSACTION, CO HAS SECURED FINANCING COMMITMENT OF $400 MILLION FROM BARCLAYS & JPMORGAN-CHASE BANK​ \n* Q4 REVENUE VIEW $114.2 MILLION -- THOMSON REUTERS I/B/E/S \n* AS OF DECEMBER 31, 2017, SEATTLE GENETICS HAD APPROXIMATELY $413 MILLION IN CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-31T13:34:00.000+02:00", "crawled": "2018-01-31T13:55:44.000+02:00", "highlightTitle": ""}